Have a feature idea you'd love to see implemented?
Let us know!
AIM AIM ImmunoTech Inc
Price (delayed)
$0.19
Market cap
$12.1M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.47
Enterprise value
$14.59M
AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases, including COVID-19, the disease
Highlights
The company's EPS rose by 18% QoQ but it fell by 9% YoY
The net income has decreased by 15% YoY but it has increased by 15% from the previous quarter
AIM ImmunoTech's equity has shrunk by 87% YoY and by 52% QoQ
AIM ImmunoTech's quick ratio has plunged by 85% YoY and by 38% from the previous quarter
Key stats
What are the main financial stats of AIM
Market
Valuations
Earnings
Shares outstanding
63.71M
Market cap
$12.1M
Enterprise value
$14.59M
Price to earnings (P/E)
N/A
Price to book (P/B)
3.73
Price to sales (P/S)
57.68
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
76.79
Revenue
$190,000
Gross profit
$154,000
Net income
-$23.93M
EBIT
-$23.48M
EBITDA
-$23.1M
Free cash flow
-$20.65M
Per share
Balance sheet
Liquidity
EPS
-$0.47
EPS diluted
-$0.47
Free cash flow per share
-$0.36
Book value per share
$0.05
Revenue per share
$0
TBVPS
$0.19
Total assets
$13.59M
Total liabilities
$10.68M
Debt
$3.4M
Equity
$2.91M
Working capital
-$2.53M
Debt to equity
1.17
Current ratio
0.75
Quick ratio
0.71
Net debt/EBITDA
-0.11
Margins
Efficiency
Dividend
EBITDA margin
-12,157.9%
Gross margin
81.1%
Net margin
-12,594.2%
Operating margin
-14,694.2%
Return on assets
-147.5%
Return on equity
-397.6%
Return on invested capital
-610.6%
Return on capital employed
-673.1%
Return on sales
-12,355.8%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
AIM stock price
How has the AIM ImmunoTech stock price performed over time
Intraday
-0.58%
1 week
-13.24%
1 month
-5%
1 year
-60.82%
YTD
-56.81%
QTD
-29.63%
Financial performance
How have AIM ImmunoTech's revenue and profit performed over time
Revenue
$190,000
Gross profit
$154,000
Operating income
-$27.92M
Net income
-$23.93M
Gross margin
81.1%
Net margin
-12,594.2%
The company's operating margin fell by 21% YoY but it rose by 6% QoQ
The operating income has contracted by 19% YoY but it has grown by 12% from the previous quarter
The net margin has declined by 17% year-on-year but it rose by 10% since the previous quarter
The net income has decreased by 15% YoY but it has increased by 15% from the previous quarter
Growth
What is AIM ImmunoTech's growth rate over time
Valuation
What is AIM ImmunoTech stock price valuation
P/E
N/A
P/B
3.73
P/S
57.68
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
76.79
The company's EPS rose by 18% QoQ but it fell by 9% YoY
The P/B is 133% higher than the 5-year quarterly average of 1.6
AIM ImmunoTech's equity has shrunk by 87% YoY and by 52% QoQ
AIM's P/S is 80% below its 5-year quarterly average of 292.9 and 43% below its last 4 quarters average of 101.6
AIM ImmunoTech's revenue has decreased by 5% QoQ
Efficiency
How efficient is AIM ImmunoTech business performance
The return on invested capital has dropped by 172% year-on-year
AIM's ROA has shrunk by 147% YoY and by 4.1% QoQ
The ROE has plunged by 55% from the previous quarter
The company's return on sales fell by 15% YoY but it rose by 11% QoQ
Dividends
What is AIM's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for AIM.
Financial health
How did AIM ImmunoTech financials performed over time
The total assets is 27% greater than the total liabilities
The company's total liabilities has surged by 103% YoY and by 11% QoQ
AIM ImmunoTech's quick ratio has plunged by 85% YoY and by 38% from the previous quarter
The debt is 17% greater than the equity
AIM's debt to equity has surged by 113% since the previous quarter
AIM ImmunoTech's equity has shrunk by 87% YoY and by 52% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.